Nature of Business (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Contracts from NIH and NIAID, description			The Company is currently developing RiVax® under a NIAID contract of up to $21.2 million over six years, and a one-year NIH grant of $150,000 in support of its SGX942 pediatric program. In addition, the Company has a subcontract of approximately $700,000 from a NIAID grant over five years for its thermostabilization technology, and a DTRA subcontract of approximately $600,000 over three years for SGX943.
Accumulated deficit	$ (185,883,709)		$ (185,883,709)		$ (175,525,612)
Net loss	(2,776,763)	$ (2,123,521)	(10,358,097)	$ (3,763,148)
Cash in operations			(4,338,530)	(2,808,372)
Cash and cash equivalents	11,168,305	$ 6,986,289	11,168,305	$ 6,986,289	5,420,708	$ 8,983,717
Net change in cash and cash equivalent			$ 5,747,597
Percentage change in cash and cash equivalent			106.00%
Working capital	$ 5,992,411		$ 5,992,411		$ 1,181,249
Increase in cash and cash equivalents			$ 4,811,162
Increase in working capital, percentage			407.00%
Government contract and grant funding available			$ 1,540,000
Remaining from FBR sales agreement, description			● The Company has up to $1.5 million remaining from the FBR Sales Agreement as of August 10, 2020 under the prospectus supplement filed April 10, 2020.
Increase (Decrease) in Notes Payable, Related Parties, Current			$ 417,830